65017-57-4

Usage

Uses

Used in Pharmaceutical Industry:
4-AMINOMETHYL-1-N-BUTYLPIPERIDINE is used as a precursor in the synthesis of neuroactive compounds targeting the central nervous system. Its unique chemical structure allows for the development of drugs with potential applications in treating neurological disorders and conditions.
Used in Agrochemical Industry:
4-AMINOMETHYL-1-N-BUTYLPIPERIDINE serves as a building block in the production of agrochemicals, contributing to the development of effective and targeted pesticides and other agricultural chemicals.
Used in Polymer Production:
4-AMINOMETHYL-1-N-BUTYLPIPERIDINE is utilized as a key component in the synthesis of polymers and other industrial materials, enhancing their properties and expanding their applications in various industries.
Used in Organic Compound Synthesis:
Due to its versatile chemical structure, 4-AMINOMETHYL-1-N-BUTYLPIPERIDINE is employed as an intermediate in the preparation of a wide range of organic compounds, facilitating the development of new chemical entities with diverse applications across various fields.

InChI:InChI=1/C10H22N2/c1-2-3-6-12-7-4-10(9-11)5-8-12/h10H,2-9,11H2,1H3

Upstream product

• 109-65-9 1-bromo-butane 
• 39546-32-2 4-carboxamidopiperidine 
• 66073-48-1 4-carboxamide-1-butylpiperidine 
• 7144-05-0 4-Aminomethylpiperidine 
• 1027516-22-8 1-Butyl-piperidine-4-carbonitrile 

Downstream Products

• 371971-18-5 N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-7-benzyloxy-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide 
• 1246551-95-0 4-amino-N-((1-butylpiperidin-4-yl)methyl)-3-methoxybenzamide 

Relevant academic research and scientific papers

An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors

Sphingosine kinase 1 (SphK1), the enzyme that produces the bioactive sphingolipid metabolite, sphingosine-1-phosphate, is a promising new molecular target for therapeutic intervention in cancer and inflammatory diseases. In view of its importance, the main objective of this work was to find new and more potent inhibitors for this enzyme possessing different structural scaffolds than those of the known inhibitors. Our theoretical and experimental study has allowed us to identify two new structural scaffolds (three new compounds), which could be used as starting structures for the design and then the development of new inhibitors of SphK1. Our study was carried out in different steps: virtual screening, synthesis, bioassays and molecular modelling. From our results, we propose a new dihydrobenzo[b]pyrimido[5,4-f]azepine and two alkyl{3-/4-[1-hydroxy-2-(4-arylpiperazin-1-yl)ethyl]phenyl}carbamates as initial structures for the development of new inhibitors. In addition, our molecular modelling study using QTAIM calculations, allowed us to describe in detail the molecular interactions that stabilize the different Ligand-Receptor complexes. Such analyses indicate that the cationic head of the different compounds must be refined in order to obtain an increase in the binding affinity of these ligands.

Preparation of 1-butyl-4-piperidinylmethylamine

A process for the preparation of 1-butyl-4-piperidinylmethylamine using toluene as a solvent is disclosed.

Indazole derivatives having monocyclic amine

An indazole compound having the formula (I): wherein: R1 is hydrogen, C1 -C6 alkyl, C3 -C6 alkenyl or C3 -C6 cycloalkyl; Q is carbonyl, thiocarbonyl or methylene; and R2 is a group of the formula (II) or (IV); STR1 wherein R1 is C1 -C6 alkyl, C3 -C6 alkenyl or benzyl, of which a phenyl group thereof is optionally mono- or di-substituted by the same or different halogen or methoxy; m is 0 to 2; n and o is 1 or 2. The compound exhibits 5-HT4 receptor agonist activity.

Synthesis and pharmacological evaluation of carboxamide derivatives as selective serotoninergic 5-HT4 receptor agonists

A number of new carboxamide derivatives were synthesized. The affinity of these compounds for the serotoninergic 5-HT4 receptor was evaluated by use of radioligand-binding techniques. The agonistic activity was evaluated as the contractile effect of the ascending colon isolated from guinea-pigs. Among these compounds, 4-amino-5-chloro-2-methoxy-N-[l-[2- [(methylsulfonyl)amino]ethly]-4piperidinylmethyl]benzamide (24) showed a high affinity for the 5-HT4 receptor (Ki = 9.6 nM). Compound 24 displayed a higher affinity for 5-HT4 receptors than the other receptors, including, 5- HT3 and dopamine D2 receptors. In addition, compound 24 was confirmed to be a potent 5-HT4 receptor agonist (ED50 = 7.0 nM). An interaction model between compound 24 and 5-HT4 receptor was proposed.

Benzimidazole derivatives. Part 1: Synthesis and structure-activity relationships of new benzimidazole-4-carboxamides and carboxylates as potent and selective 5-HT4 receptor antagonists

New benzimidazole-4-carboxamides 1-16 and -carboxylates 17-26 were synthesized and evaluated for binding affinity at serotonergic 5-HT4 and 5- HT3 receptors in the CNS. Most of the synthesized compounds exhibited moderate-to-very high affinity (in many cases subnanomolar) for the 5-HT4 binding site and no significant affinity for the 5-HT3 receptor. SAR observations and structural analyses (molecular modeling, INSIGHT II) indicated that the presence of a voluminous substituent in the basic nitrogen atom of the amino moiety and a distance of ca. 8.0 A from this nitrogen to the aromatic ring are of great importance for high affinity and selectivity for 5-HT4 receptors. These results confirm our recently proposed model for recognition by the 5-HT4 binding site. Amides 12-15 and esters 24 and 25 bound at central 5-HT4 sites with very high affinity (K(i) = 0.11-2.9 nM) and excellent selectivity over serotonin 5-HT3, 5-HT(2A), and 5-HT(1A) receptors (K(i) > 1000-10,000 nM). Analogues 12 (K(i)(5-HT4) = 0.32 nM), 13 (K(i)(5-HT4) = 0.11 nM), 14 (K(i)(5-HT4) = 0.29 nM) and 15 (K(i)(5-HT4) = 0.54 nM) were pharmacologically characterized as selective 5-HT4 antagonists in the isolated guinea pig ileum (pA2 = 7.6, 7.9, 8.2 and 7.9, respectively), with a potency comparable to the 5-HT4 receptor antagonist RS 39604 (pA2 = 8.2). The benzimidazole-4-carboxylic acid derivatives described in this paper represent a novel class of potent and selective 5-HT4 receptor antagonists. In particular, compounds 12-15 could be interesting pharmacological tools for the understanding of the role of 5-HT4 receptors. (C) 1999 Elsevier Science Ltd.